Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Approved by the FDA in 2002
36(12):2541-50
Acadesine (500 μM) increases the ZMP content in extracts of isolated hepatocytes after up to 30-40 min treatment
5-difluoro-4-{[2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]oxy}phenyl)-N1-phenylcyclopropane-1
4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35
Trastuzumab deruxtecan othenic acid Approved by the FDA inTrastuzumab deruxtecan (DS 8201a) is an anti human epidermal growth factor receptor 2 (HER2) antibody drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti HER2 antibody, an enzymatically cleavable peptide linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2 positive breast cancer and gastric cancer. Product information CAS Number: 1826843 81 5 Molecular Weight: 493. 48 Formula:
US$ 600.00
US$ 1050.00
US$ 347.50